<div id="readability-page-1"><p>Barclays analyst Eliana Merle maintained a Buy rating on Insmed today and set a price target of $237.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Merle is a 3-star analyst with an average return of <span>3.8%</span> and a 41.22% success rate. Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and BioMarin Pharmaceutical.</p> <p>In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $243.00 price target.</p></div>

INSM

SBIO

<p>Barclays analyst Eliana Merle has reaffirmed a Buy rating on Insmed (INSM) with a price target of $237.00. Merle, a 3-star analyst with a 41.22% success rate, focuses on the Healthcare sector. Additionally, TD Cowen also maintained a Buy rating on Insmed, setting a price target of $243.00.</p>

Tip Ranks

Insmed

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Invesco Dorsey Wright Healthcare Momentum ETF

iShares Global Healthcare

VanEck Biotech ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VG Health

Barclays

Alnylam Pharma

Bridgebio Pharma

BioMarin Pharma

Barclays Reaffirms Their Buy Rating on Insmed (INSM)